Recent Updates
Recently added Catalysts
CRMD Negative Sentiment Score: 30/100

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: CorMedix Inc. is currently facing an investigation by Bragar Eagel & Squire, P.C. on behalf of stockholders, concerning potential violations of federal securities laws. This follows their recent earnings call where the company indicated that it anticipates net price erosion beginning in the second quarter of 2025. As a result of this news, the stock price has declined. Shareholders who suffered losses are encouraged to contact the law firm.

Market Sentiment Analysis

CONCERNS & RISKS

  • CorMedix is under investigation for potential violations of federal securities laws.
  • The company's earnings call indicated expected net price erosion starting in Q2 2025.
  • Following the earnings report, CorMedix's stock price dropped.

Full Press Release Details

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) on behalf of CorMedix stockholders. Our investigation concerns whether CorMedix has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On March 25, 2025, Cormedix reported fourth quarter and full year 2024 financial results. During the Company’s earnings call held the same day, Cormedix noted that “we do expect to begin to see some net price erosion beginning in the second quarter of 2025.” Following this news, the price of the Company’s stock dropped.
If you purchased or otherwise acquired CorMedix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What claims are being investigated against CorMedix?

Bragar Eagel & Squire is investigating potential claims involving CorMedix's compliance with federal securities laws and possible unlawful business practices.

Why did CorMedix's stock price drop recently?

The stock price of CorMedix fell after the company announced expected net price erosion in Q2 2025 during its earnings call.

How can I participate in the CorMedix investigation?

To participate, contact Bragar Eagel & Squire via email or phone to discuss your rights and interests regarding CorMedix.

Is there a cost to participate in the investigation?

There is no cost or obligation to participate in the investigation concerning CorMedix.

What does Bragar Eagel & Squire specialize in?

Bragar Eagel & Squire specializes in representing investors in commercial and securities litigation across federal and state courts.

Last updated: Mar 28, 2025